reconciliation_NN to_TO US_NNP accounting_NN principles_NNS Reconciliation_NNP to_TO Accounting_NNP Principles_NNPS The_DT financial_JJ statements_NNS of_IN the_DT Group_NNP are_VBP prepared_VBN in_IN accordance_NN with_IN UK_NNP GAAP_NNP Generally_RB Accepted_JJ Accounting_NN Principles_NNS which_WDT differs_VBZ in_IN certain_JJ respects_NNS from_IN US_NNP GAAP_NNP ._.
The_DT tables_NNS below_IN summarise_NN the_DT material_NN adjustments_NNS to_TO the_DT loss_NN profit_NN for_IN the_DT year_NN and_CC shareholders_NNS funds_NNS which_WDT would_MD be_VB required_VBN if_IN US_NNP GAAP_NNP had_VBD been_VBN applied_VBN instead_RB of_IN UK_NNP GAAP_NNP ._.
Year_NN to_TO Year_NN to_TO 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD Notes_NNP 000_CD 000_CD Loss_NN profit_NN under_IN UK_NNP GAAP_NNP 43,223_CD 1,109_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Amortisation_NNP of_IN goodwill_NN and_CC other_JJ intangibles_NNS 1a_NNS ,_, c_NN ,_, d_SYM 3,664_CD 3,399_CD Depreciation_NN of_IN tangible_JJ fixed_JJ assets_NNS 1b_VBP 823_CD 518_CD Investments_NNP 1c_CD 1,893_CD Write-off_NN of_IN acquired_VBN in-process_JJ R&D_NNP 1e_CD 4,646_CD Deferred_JJ taxes_NNS 1c_VBP 139_CD 401_CD Share-based_JJ compensation_NN 4_CD 751_CD 181_CD Revenue_NN recognition_NN 5_CD 13,386_CD 26,987_CD Sale_NNP of_IN royalty_NN interests_NNS Revenue_NN recognition_NN 6_CD 6,126_CD 14,219_CD Interest_NN expense_NN 6_CD 9,609_CD 5,850_CD Royalty_NN payments_NNS 6_CD 3,144_CD 664_CD Financial_NNP instruments_NNS 8_CD 146_CD 531_CD Net_JJ loss_NN under_IN US_NNP GAAP_NNP 37,084_CD 45,261_CD Net_JJ loss_NN per_IN Ordinary_NNP Share_NNP under_IN US_NNP GAAP_NNP pence_NN 6.1_CD p_NN 7.8_CD p_NN 31_CD December_NNP 2003_CD 31_CD December_NNP 2002_CD Notes_NNP 000_CD 000_CD Shareholders_NNS funds_NNS under_IN UK_NNP GAAP_NNP 86,265_CD 124,270_CD US_NNP GAAP_NNP adjustments_NNS :_: Purchase_NN accounting_NN and_CC goodwill_NN Goodwill_NNP 1a_CD ,_, c_NN ,_, d_SYM 85,226_CD 83,719_CD Other_JJ intangible_JJ fixed_JJ assets_NNS 1a_NNS ,_, c_NN 4,378_CD 4,344_CD Tangible_JJ fixed_JJ assets_NNS 1b_VBP 7,946_CD 7,930_CD Investments_NNP 1c_CD 1,893_CD Deferred_JJ taxes_NNS 1c_VBP 1,578_CD 1,439_CD Contingent_JJ consideration_NN charged_VBN to_TO goodwill_NN reserve_NN 1e_CD 22,620_CD 22,620_CD Shares_NNS issued_VBN relating_VBG to_TO contingent_JJ consideration_NN 3_CD 11,310_CD 11,310_CD Shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN ,_, deferred_VBN shares_NNS and_CC shares_NNS issued_VBN 2_CD 11,310_CD 11,310_CD Share-based_JJ compensation_NN 4_CD 1,056_CD 305_CD Employee_NN benefit_NN trust_NN 7_CD 1,800_CD 1,859_CD Deferred_JJ revenue_NN 5_CD 10,887_CD 23,179_CD Funding_NNP liabilities_NNS 6_CD 51,224_CD 37,698_CD Financial_NNP instruments_NNS 8_CD 354_CD 500_CD Shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP 101,732_CD 138,530_CD SkyePharma_NNP annual_JJ report_NN 2003_CD 86_CD 87_CD reconciliation_NN to_TO US_NNP accounting_NN principles_NNS continued_VBD Summary_NNP of_IN Material_NNP Differences_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP The_NNP adjustments_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP relating_VBG to_TO the_DT RTP_NNP acquisition_NN are_VBP mainly_RB differences_NNS in_IN i_FW the_DT valuation_NN 1_CD Business_NNP combinations_NNS Under_IN both_DT UK_NNP and_CC US_NNP GAAP_NNP of_IN contingent_JJ purchase_NN price_NN consideration_NN and_CC ii_VB the_DT methods_NNS the_DT acquisitions_NNS of_IN Jago_NNP Holdings_NNP AG_NNP ,_, SkyePharma_NNP Production_NNP of_IN purchase_NN price_NN allocation_NN ._.
SAS_NNP formerly_RB Laboratories_NNPS Novalis_NNP Production_NNP SAS_NNP ,_, SkyePharma_NNP Inc._NNP formerly_RB DepoTech_NNP Corporation_NNP ,_, SkyePharma_NNP Canada_NNP Inc._NNP ._.
Contingent_JJ consideration_NN Under_IN UK_NNP GAAP_NNP ,_, contingent_JJ consideration_NN formerly_RB RTP_NNP Pharma_NNP Inc._NNP and_CC SkyePharma_NNP AB_NNP are_VBP accounted_VBN had_VBD not_RB been_VBN recognized_VBN as_IN part_NN of_IN the_DT acquisition_NN cost_NN ._.
The_DT deferred_VBN for_IN as_IN acquisitions_NNS purchases_NNS ._.
Both_DT UK_NNP and_CC US_NNP GAAP_NNP require_VBP the_DT consideration_NN became_VBD payable_JJ on_IN 30_CD June_NNP 2003_CD and_CC the_DT fair_JJ value_NN purchase_NN consideration_NN to_TO be_VB allocated_VBN to_TO the_DT net_JJ assets_NNS acquired_VBN of_IN 3,690,211_CD additional_JJ SkyePharma_NNP shares_NNS were_VBD recorded_VBN as_RB at_IN their_PRP$ fair_JJ value_NN at_IN the_DT date_NN of_IN acquisition_NN ,_, with_IN the_DT difference_NN goodwill_NN during_IN the_DT year_NN ._.
Under_IN US_NNP GAAP_NNP ,_, the_DT Company_NN applied_VBD between_IN the_DT consideration_NN and_CC the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS EITF_NNP 97-15_CD ,_, Accounting_NNP for_IN Contingency_NNP Arrangements_NNP Based_VBD on_IN acquired_VBN treated_VBN as_IN goodwill_NN ._.
In_IN the_DT allocation_NN of_IN consideration_NN ,_, Security_NNP Prices_NNS in_IN a_DT Purchase_NNP Business_NNP Combination_NNP to_TO estimate_VB and_CC the_DT treatment_NN of_IN contingent_JJ consideration_NN ,_, certain_JJ differences_NNS the_DT contingent_JJ consideration_NN as_IN of_IN the_DT acquisition_NN date_NN ._.
Under_IN between_IN UK_NNP and_CC US_NNP GAAP_NNP arise_VB as_RB set_VBN out_RP below_IN ._.
EITF_NNP 97-15_CD a_DT contingency_NN arrangement_NN that_WDT does_VBZ not_RB result_VB in_IN a_DT guarantee_NN of_IN the_DT minimum_JJ value_NN of_IN the_DT total_JJ consideration_NN should_MD a_DT Goodwill_NNP and_CC other_JJ intangible_JJ fixed_JJ assets_NNS Prior_RB to_TO the_DT be_VB recorded_VBN at_IN an_DT amount_NN equal_JJ to_TO the_DT maximum_JJ number_NN of_IN shares_NNS introduction_NN of_IN FRS10_NNP ,_, as_IN permissible_JJ under_IN UK_NNP GAAP_NNP ,_, no_DT that_WDT could_MD be_VB issued_VBN multiplied_VBN by_IN the_DT fair_JJ value_NN per_IN share_NN at_IN the_DT intangible_JJ assets_NNS had_VBD been_VBN recognized_VBN as_IN a_DT result_NN of_IN purchase_NN date_NN of_IN the_DT acquisition_NN ._.
However_RB ,_, the_DT recorded_VBN amount_NN may_MD not_RB accounting_VBG as_IN the_DT intangible_JJ assets_NNS were_VBD considered_VBN to_TO be_VB an_DT exceed_VB the_DT target_NN value_NN of_IN the_DT consideration_NN issued_VBN at_IN the_DT date_NN integral_JJ part_NN of_IN the_DT business_NN acquired_VBD and_CC were_VBD ,_, therefore_RB ,_, included_VBD of_IN acquisition_NN i._FW e._FW the_DT lowest_JJS total_JJ value_NN at_IN which_WDT additional_JJ within_IN goodwill_NN and_CC eliminated_VBN against_IN shareholders_NNS funds_NNS ._.
Where_WRB consideration_NN would_MD not_RB be_VB required_VBN to_TO be_VB issued_VBN ._.
The_DT subsequent_JJ the_DT aggregate_NN of_IN the_DT fair_JJ values_NNS of_IN the_DT net_JJ assets_NNS acquired_VBN exceeded_VBD issuance_NN of_IN additional_JJ consideration_NN resulting_VBG from_IN either_DT of_IN these_DT the_DT cost_NN of_IN the_DT acquired_VBN net_JJ assets_NNS resulting_VBG in_IN negative_JJ goodwill_NN ,_, security_NN price_NN contingencies_NNS does_VBZ not_RB change_VB the_DT recorded_VBN cost_NN such_JJ excess_NN was_VBD credited_VBN directly_RB to_TO reserves_NNS ._.
The_DT Group_NNP adopted_VBD of_IN the_DT acquisition_NN ._.
The_DT application_NN of_IN the_DT provisions_NNS of_IN EITF_NNP 97-15_CD transitional_JJ provisions_NNS under_IN FRS10_NNP and_CC accordingly_RB did_VBD not_RB reinstate_VB has_VBZ resulted_VBN in_IN a_DT 2.6_CD million_CD increase_NN in_IN the_DT purchase_NN consideration_NN ._.
goodwill_NN previously_RB eliminated_VBN against_IN reserves_NNS as_IN an_DT intangible_JJ asset_NN ._.
Purchase_NN price_NN allocation_NN Under_IN US_NNP GAAP_NNP an_DT intangible_JJ asset_NN US_NNP GAAP_NNP requires_VBZ an_DT allocation_NN of_IN the_DT purchase_NN consideration_NN shall_MD be_VB recognized_VBN as_IN an_DT asset_NN apart_RB from_IN goodwill_NN if_IN it_PRP arises_VBZ to_TO identifiable_JJ intangible_JJ assets_NNS ,_, including_VBG any_DT resulting_VBG from_IN from_IN contractual_JJ or_CC other_JJ legal_JJ rights_NNS or_CC if_IN it_PRP is_VBZ separable_JJ ,_, that_DT is_VBZ ,_, research_NN and_CC development_NN ._.
Goodwill_NN and_CC identifiable_JJ intangible_JJ it_PRP is_VBZ capable_JJ of_IN being_VBG separated_VBN or_CC divided_VBN from_IN the_DT acquired_VBN entity_NN fixed_VBN assets_NNS are_VBP reflected_VBN as_IN assets_NNS ._.
Prior_RB to_TO 2002_CD ,_, goodwill_NN was_VBD and_CC sold_VBD ,_, transferred_VBN ,_, licensed_VBN ,_, rented_VBN ,_, or_CC exchanged_VBD ._.
In_IN addition_NN ,_, amortised_VBN over_IN its_PRP$ useful_JJ life_NN ,_, with_IN the_DT exception_NN of_IN goodwill_NN arising_VBG US_NNP GAAP_NNP requires_VBZ amounts_NNS allocated_VBN to_TO acquired_VBN in-process_NN on_IN acquisitions_NNS made_VBN after_IN 30_CD June_NNP 2001_CD ._.
Effective_JJ 1_CD January_NNP 2002_CD research_NN and_CC development_NN that_WDT do_VBP not_RB have_VB an_DT alternative_JJ use_NN goodwill_NN is_VBZ no_RB longer_RB amortised_VBN under_IN US_NNP GAAP_NNP ,_, but_CC instead_RB subject_JJ to_TO be_VB expensed_VBN through_IN earnings_NNS in_IN the_DT period_NN of_IN acquisition_NN ._.
This_DT results_NNS in_IN a_DT reversal_NN of_IN goodwill_NN Under_IN US_NNP GAAP_NNP ,_, the_DT investment_NN in_IN Waratah_NNP Pharmaceuticals_NNP Inc_NNP amortisation_NN charged_VBN under_IN UK_NNP GAAP_NNP ._.
``_`` Intangible_JJ fixed_JJ assets_NNS ''_'' ``_`` Waratah_NNP ''_'' ''_'' was_VBD fair_JJ valued_VBN based_VBN on_IN prices_NNS quoted_VBN by_IN the_DT recognized_VBN under_IN US_NNP GAAP_NNP purchase_NN accounting_NN requirements_NNS Canadian_JJ Venture_NNP Stock_NNP Exchange_NNP as_IN of_IN each_DT acquisition_NN date_NN ._. ''_''
are_VBP amortised_VBN over_IN their_PRP$ estimated_VBN revenue_NN earning_VBG life_NN ._.
Negative_JJ The_DT difference_NN between_IN the_DT fair_JJ value_NN and_CC the_DT equity_NN value_NN of_IN goodwill_NN ,_, if_IN any_DT ,_, is_VBZ eliminated_VBN by_IN reducing_VBG the_DT value_NN of_IN all_DT nonthe_JJ investment_NN was_VBD allocated_VBN to_TO goodwill_NN ._.
Under_IN UK_NNP GAAP_NNP ,_, current_JJ assets_NNS acquired_VBN ._.
the_DT investment_NN was_VBD fair_JJ valued_VBN when_WRB the_DT Company_NN gained_VBD control_NN in_IN December_NNP 2001_CD ._.
The_DT deferred_VBN taxation_NN impact_NN of_IN all_PDT these_DT b_NN Tangible_JJ fixed_JJ assets_NNS Prior_RB to_TO the_DT introduction_NN of_IN FRS10_CD differences_NNS has_VBZ been_VBN recognized_VBN in_IN the_DT purchase_NN price_NN allocation_NN under_IN UK_NNP GAAP_NNP for_IN business_NN acquisitions_NNS ,_, where_WRB the_DT aggregate_NN of_IN for_IN US_NNP GAAP_NNP purposes_NNS ._.
the_DT fair_JJ values_NNS of_IN the_DT net_JJ assets_NNS acquired_VBN exceeded_VBD the_DT cost_NN of_IN the_DT acquired_VBN net_JJ assets_NNS resulting_VBG in_IN negative_JJ goodwill_NN ,_, such_JJ excess_JJ In_IN January_NNP 2002_CD Waratah_NNP merged_VBD with_IN Transition_NN Therapeutics_NNPS Inc._NNP was_VBD credited_VBN directly_RB to_TO reserves_NNS ._.
``_`` Under_IN US_NNP GAAP_NNP such_JJ excess_NN is_VBZ ''_'' ``_`` Transition_NN ''_'' ''_'' and_CC Waratah_NNP shareholders_NNS were_VBD awarded_VBN 0.83333_CD eliminated_VBN by_IN proportionately_RB reducing_VBG the_DT value_NN of_IN the_DT non-current_JJ Transition_NN shares_NNS for_IN every_DT one_CD share_NN of_IN Waratah_NNP held_VBD ._. ''_''
GAAP_NNP ,_, the_DT Group_NNP continued_VBD to_TO account_VB for_IN the_DT investment_NN at_IN cost_NN less_JJR provision_NN for_IN permanent_JJ diminution_NN in_IN value_NN ._.
S_NNP GAAP_NNP ,_, c_NN Acquisition_NNP of_IN RTP_NNP In_IN 2001_CD ,_, the_DT Group_NNP purchased_VBD the_DT majority_NN on_IN the_DT merger_NN date_NN the_DT Group_NNP ceased_VBD to_TO apply_VB the_DT equity_NN method_NN of_IN interest_NN of_IN RTP_NNP through_IN a_DT two-step_JJ acquisition_NN effected_VBD in_IN July_NNP and_CC accounting_NN and_CC carries_VBZ the_DT investment_NN in_IN Transition_NN at_IN adjusted_JJ December_NNP 2001_CD ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT aggregate_JJ purchase_NN price_NN was_VBD cost_VBN less_JJR provision_NN for_IN permanent_JJ diminution_NN in_IN value_NN ._.
39.4_CD million_CD ,_, including_VBG 35.3_CD million_CD of_IN ordinary_JJ shares_NNS ,_, 3.5_CD million_CD of_IN cash_NN ,_, and_CC 0.6_CD million_CD in_IN acquisition_NN costs_NNS ._.
The_DT acquisition_NN was_VBD d_SYM Goodwill_NNP Under_IN UK_NNP GAAP_NNP goodwill_NN is_VBZ being_VBG amortised_VBN over_IN recorded_VBN using_VBG the_DT purchase_NN method_NN of_IN accounting_NN under_IN both_DT 20_CD years_NNS on_IN a_DT straight-line_JJ basis_NN ._.
Under_IN US_NNP GAAP_NNP ,_, goodwill_NN is_VBZ not_RB UK_NNP and_CC US_NNP GAAP_NNP ._.
Goodwill_NN was_VBD determined_VBN as_IN the_DT difference_NN amortised_VBN but_CC is_VBZ subject_JJ to_TO regular_JJ impairment_NN tests_NNS ._.
In_IN addition_NN ,_, between_IN the_DT purchase_NN price_NN and_CC the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS under_IN US_NNP GAAP_NNP ,_, the_DT excess_NN of_IN the_DT fair_JJ value_NN of_IN the_DT net_JJ assets_NNS acquired_VBD acquired_VBN ._.
Under_IN both_DT UK_NNP and_CC US_NNP GAAP_NNP the_DT investment_NN in_IN RTP_NNP was_VBD in_IN December_NNP 2001_CD over_IN the_DT purchase_NN consideration_NN negative_JJ equity_NN accounted_VBD for_IN until_IN control_NN was_VBD gained_VBN on_IN 27_CD December_NNP 2001_CD goodwill_NN resulting_VBG from_IN difference_NN in_IN the_DT purchase_NN price_NN allocation_NN and_CC consolidated_JJ from_IN that_DT date_NN on_IN ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD has_VBZ been_VBN allocated_VBN as_IN a_DT pro_JJ rata_JJ reduction_NN of_IN the_DT non-current_JJ 3_CD Shares_NNS issued_VBN related_VBN to_TO contingent_JJ consideration_NN In_IN April_NNP 2002_CD ,_, assets_NNS acquired_VBD including_VBG in-process_JJ research_NN and_CC development_NN ._.
all_DT contingencies_NNS related_VBN to_TO the_DT Deferred_NNP A_NNP Shares_NNP were_VBD removed_VBN based_VBN on_IN the_DT first_JJ commercial_JJ launch_NN of_IN Paxil_NNP CR_NNP ._.
e_LS In-process_JJ research_NN and_CC development_NN costs_NNS In_IN 2002_CD ,_, the_DT Group_NNP In_IN connection_NN with_IN the_DT removal_NN of_IN these_DT contingencies_NNS ,_, in_IN 2002_CD acquired_VBD the_DT drug_NN delivery_NN business_NN of_IN Bioglan_NNP AB_NNP ._.
A_DT charge_NN of_IN the_DT Group_NNP issued_VBD 12_CD million_CD Ordinary_NNP Shares_NNP to_TO Dr._NNP Gonella_NNP ,_, 4.6_CD million_CD was_VBD expensed_VBN in_IN the_DT year_NN ended_VBD 31_CD December_NNP 2002_CD the_DT vendor_NN of_IN Jago_NNP ._.
Under_IN US_NNP GAAP_NNP ,_, these_DT shares_NNS were_VBD recorded_VBN whereas_IN under_IN UK_NNP GAAP_NNP this_DT was_VBD treated_VBN as_IN goodwill_NN ._.
In_IN 2001_CD ,_, the_DT within_IN shareholders_NNS funds_NNS at_IN the_DT market_NN value_NN at_IN the_DT date_NN the_DT Group_NNP purchased_VBD the_DT majority_NN interest_NN of_IN RTP_NNP through_IN a_DT two-step_JJ contingencies_NNS were_VBD removed_VBN ._.
acquisition_NN effected_VBD in_IN July_NNP and_CC December_NNP 2001_CD ._.
The_DT acquisitions_NNS were_VBD recorded_VBN using_VBG the_DT purchase_NN method_NN of_IN accounting_NN under_IN Under_IN UK_NNP GAAP_NNP the_DT shares_NNS were_VBD recorded_VBN at_IN the_DT market_NN price_NN both_DT UK_NNP and_CC US_NNP GAAP_NNP ._.
at_IN the_DT date_NN of_IN issuance_NN of_IN deferred_JJ shares_NNS 20_CD July_NNP 2000_CD ._.
The_DT adjustment_NN reverses_VBZ the_DT value_NN of_IN equity_NN share_NN capital_NN and_CC The_DT adjustments_NNS between_IN UK_NNP and_CC US_NNP GAAP_NNP in_IN respect_NN of_IN the_DT premium_NN in_IN the_DT amount_NN of_IN 11.3_CD million_CD ._.
A_DT corresponding_JJ RTP_NNP acquisition_NN relate_VBP mainly_RB to_TO differences_NNS in_IN the_DT valuation_NN of_IN adjustment_NN in_IN the_DT amount_NN of_IN 9.4_CD million_CD has_VBZ been_VBN recorded_VBN within_IN purchase_NN price_NN consideration_NN ,_, the_DT methods_NNS of_IN purchase_NN price_NN Goodwill_NNP and_CC other_JJ intangible_JJ fixed_JJ assets_NNS that_WDT represents_VBZ the_DT fair_JJ allocation_NN and_CC the_DT amortisation_NN of_IN goodwill_NN ._.
In_IN 2001_CD ,_, this_DT resulted_VBD value_NN of_IN shares_NNS issued_VBN under_IN US_NNP GAAP_NNP ._.
in_IN a_DT 5.3_CD million_CD increase_NN in_IN purchase_NN consideration_NN and_CC differences_NNS in_IN the_DT amounts_NNS assigned_VBN to_TO certain_JJ tangible_JJ and_CC 4_CD Share-based_JJ compensation_NN Under_IN UK_NNP GAAP_NNP ,_, the_DT Company_NN does_VBZ intangible_JJ fixed_VBN assets_NNS ,_, investments_NNS and_CC related_VBN deferred_JJ taxes_NNS ._.
not_RB recognize_VB compensation_NN expense_NN associated_VBN with_IN its_PRP$ stock_NN Under_IN US_NNP GAAP_NNP amounts_VBZ allocated_VBN to_TO acquired_VBN in-process_NN option_NN plans_VBZ granted_VBN to_TO employees_NNS as_IN the_DT exercise_NN price_NN of_IN the_DT research_NN and_CC development_NN that_WDT do_VBP not_RB have_VB an_DT alternative_JJ use_NN options_NNS equal_VBP the_DT market_NN value_NN at_IN the_DT date_NN of_IN grant_NN ._.
have_VBP been_VBN expensed_VBN through_IN earnings_NNS in_IN the_DT period_NN of_IN acquisition_NN :_: under_IN UK_NNP GAAP_NNP ,_, certain_JJ of_IN these_DT amounts_NNS are_VBP not_RB separately_RB Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP applies_VBZ Accounting_NNP Principles_NNP Board_NNP identified_VBD but_CC considered_VBD part_NN of_IN goodwill_NN ._.
In_IN addition_NN ,_, under_IN UK_NNP Opinion_NNP APB_NNP No._NN ._.
25_CD ,_, Accounting_NNP for_IN Stock_NNP Issued_NNP to_TO Employees_NNS ,_, GAAP_NNP goodwill_NN is_VBZ being_VBG amortised_VBN over_IN 20_CD years_NNS on_IN a_DT straight-line_JJ and_CC related_JJ interpretations_NNS in_IN accounting_NN for_IN its_PRP$ plans_NNS ._.
Accordingly_RB ,_, basis_NN while_IN under_IN US_NNP GAAP_NNP ,_, goodwill_NN resulting_VBG from_IN this_DT compensation_NN expense_NN has_VBZ been_VBN recognized_VBN for_IN performance-based_JJ acquisition_NN was_VBD not_RB amortised_VBN ._.
compensation_NN plans_NNS variable_JJ plans_NNS where_WRB it_PRP is_VBZ probable_JJ that_IN the_DT performance_NN criteria_NNS will_MD be_VB met_VBN and_CC the_DT options_NNS exercised_VBN prior_RB f_SYM Contingent_JJ consideration_NN charged_VBN to_TO goodwill_NN The_DT Group_NNP to_TO the_DT expiration_NN of_IN the_DT options_NNS issued_VBN under_IN these_DT plans_NNS ._.
No_DT effected_VBD the_DT acquisition_NN of_IN Jago_NNP and_CC Krypton_NNP through_IN the_DT exchange_NN compensation_NN expense_NN has_VBZ been_VBN recognized_VBN for_IN those_DT plans_NNS that_IN of_IN warrants_NNS and_CC shares_NNS ._.
The_DT issuance_NN of_IN certain_JJ of_IN these_DT warrants_NNS are_VBP considered_VBN fixed_VBN option_NN plans_NNS under_IN APB_NNP 25_CD and_CC where_WRB the_DT and_CC shares_NNS is_VBZ contingent_JJ upon_IN the_DT occurrence_NN of_IN certain_JJ future_JJ options_NNS granted_VBN under_IN the_DT plans_NNS are_VBP granted_VBN at_IN a_DT price_NN that_WDT equals_VBZ events_NNS ._.
Under_IN UK_NNP GAAP_NNP ,_, the_DT Group_NNP estimated_VBD the_DT fair_JJ value_NN of_IN the_DT market_NN price_NN at_IN the_DT date_NN of_IN grant_NN ._.
the_DT contingent_JJ consideration_NN to_TO determine_VB the_DT acquisition_NN cost_NN ._.
The_DT resulting_VBG goodwill_NN was_VBD eliminated_VBN against_IN shareholders_NNS funds_NNS ._.
5_CD Revenue_NN recognition_NN Under_IN UK_NNP GAAP_NNP contract_NN revenue_NN is_VBZ recognized_VBN when_WRB it_PRP is_VBZ earned_VBN and_CC non-refundable_JJ and_CC to_TO the_DT extent_NN Under_IN US_NNP GAAP_NNP the_DT acquisition_NN cost_NN has_VBZ been_VBN adjusted_VBN to_TO remove_VB that_IN there_EX are_VBP no_DT future_JJ obligations_NNS pursuant_JJ to_TO the_DT revenue_NN ,_, in_IN the_DT contingent_JJ consideration_NN ,_, which_WDT is_VBZ only_RB recognized_VBN when_WRB it_PRP accordance_NN with_IN the_DT contract_NN terms_NNS ._.
Refundable_JJ contract_NN revenue_NN is_VBZ determinable_JJ beyond_IN reasonable_JJ doubt_NN ,_, therefore_RB contingent_JJ is_VBZ treated_VBN as_IN deferred_VBN until_IN such_PDT a_DT time_NN as_IN it_PRP is_VBZ no_RB longer_RB consideration_NN charged_VBN to_TO goodwill_NN reserves_NNS has_VBZ been_VBN reversed_VBN refundable_JJ ._.
Under_IN US_NNP GAAP_NNP ,_, SAB_NNP 101_CD requires_VBZ deferral_JJ and_CC out_IN of_IN shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP ._.
amortisation_NN of_IN up-front_JJ licensing_NN fees_NNS where_WRB there_EX is_VBZ a_DT continuing_VBG involvement_NN with_IN the_DT licensed_JJ asset_NN through_IN the_DT provision_NN of_IN 2_CD Deferred_JJ shares_NNS and_CC shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN Under_IN research_NN and_CC development_NN services_NNS ,_, manufacturing_VBG services_NNS or_CC UK_NNP GAAP_NNP ,_, contingent_JJ consideration_NN payable_JJ in_IN connection_NN with_IN other_JJ similar_JJ activities_NNS even_RB if_IN the_DT fee_NN is_VBZ non-refundable_JJ ._.
As_IN a_DT the_DT acquisition_NN of_IN Jago_NNP is_VBZ included_VBN within_IN shareholders_NNS funds_NNS as_IN result_NN ,_, under_IN US_NNP GAAP_NNP certain_JJ non-refundable_JJ up-front_JJ payments_NNS deferred_VBN shares_NNS ._.
have_VBP been_VBN deferred_VBN over_IN the_DT development_NN period_NN of_IN the_DT contract_NN term_NN on_IN certain_JJ agreements_NNS ._.
Under_IN US_NNP GAAP_NNP ,_, contingent_JJ consideration_NN is_VBZ recognized_VBN only_RB when_WRB determinable_JJ beyond_IN reasonable_JJ doubt_NN ,_, therefore_RB deferred_VBN shares_NNS Deferred_JJ revenue_NN reflects_VBZ the_DT amount_NN of_IN revenue_NN not_RB currently_RB and_CC shares_NNS and_CC warrants_NNS to_TO be_VB issued_VBN have_VBP been_VBN reversed_VBN out_IN of_IN eligible_NN for_IN recognition_NN under_IN US_NNP GAAP_NNP as_RB well_RB as_IN the_DT reversal_NN shareholders_NNS funds_NNS under_IN US_NNP GAAP_NNP ._.
of_IN 8.8_CD million_CD 31_CD December_NNP 2002_CD :_: 7.8_CD million_CD deferred_JJ income_NN under_IN UK_NNP GAAP_NNP related_VBN to_TO the_DT sale_NN of_IN royalty_NN interests_NNS ,_, which_WDT is_VBZ treated_VBN as_IN debt_NN under_IN US_NNP GAAP_NNP ._.
SkyePharma_NNP annual_JJ report_NN 2003_CD 88_CD 89_CD reconciliation_NN to_TO US_NNP accounting_NN principles_NNS continued_VBD 6_CD Sale_NNP of_IN royalty_NN interests_NNS Under_IN UK_NNP GAAP_NNP payments_NNS received_VBD from_IN is_VBZ not_RB available_JJ for_IN the_DT delivered_VBN items_NNS then_RB the_DT residual_JJ method_NN a_DT third_JJ party_NN in_IN return_NN for_IN the_DT sale_NN of_IN a_DT proportion_NN of_IN potential_JJ future_NN must_MD be_VB used_VBN ._.
This_DT method_NN requires_VBZ that_IN the_DT amount_NN allocated_VBN royalty_NN streams_NNS from_IN a_DT selection_NN of_IN products_NNS ,_, and_CC used_VBD to_TO fund_VB the_DT to_TO the_DT undelivered_JJ items_NNS in_IN the_DT arrangement_NN is_VBZ their_PRP$ full_JJ fair_JJ value_NN ._.
internal_JJ research_NN and_CC development_NN of_IN products_NNS ,_, are_VBP reflected_VBN within_IN This_DT would_MD result_VB in_IN the_DT discount_NN ,_, if_IN any_DT ,_, being_VBG allocated_VBN to_TO the_DT other_JJ operating_NN income_NN when_WRB the_DT risk_NN of_IN reimbursement_NN has_VBZ delivered_VBN items_NNS ._.
This_DT consensus_NN is_VBZ effective_JJ prospectively_RB for_IN effectively_RB been_VBN transferred_VBN to_TO the_DT third_JJ party_NN ._.
Royalties_NNS paid_VBD arrangements_NNS entered_VBD into_IN in_IN fiscal_JJ periods_NNS beginning_VBG after_IN to_TO third_JJ parties_NNS are_VBP treated_VBN as_IN cost_NN of_IN goods_NNS sold_VBN ._.
15_CD June_NNP 2003_CD ,_, which_WDT ,_, for_IN the_DT Group_NNP ,_, is_VBZ 1_CD January_NNP 2004_CD ._.
The_DT Group_NNP is_VBZ assessing_VBG the_DT impact_NN of_IN this_DT interpretation_NN ._.
US_NNP GAAP_NNP requires_VBZ such_JJ payments_NNS to_TO be_VB recorded_VBN as_IN debt_NN where_WRB there_EX is_VBZ continuing_VBG involvement_NN in_IN the_DT generation_NN of_IN the_DT cash_NN flows_VBZ In_IN January_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD Interpretation_NNP No._NN ._.
The_DT US_NNP GAAP_NNP adjustment_NN for_IN the_DT statement_NN Consolidation_NN of_IN Variable_JJ Interest_NN Entities_NNS FIN_NNP 46_CD and_CC in_IN of_IN operations_NNS includes_VBZ the_DT reversal_NN of_IN other_JJ operating_NN income_NN December_NNP 2003_CD issued_VBD FIN46_CD R_NN ,_, a_DT revision_NN of_IN this_DT interpretation_NN ._.
recorded_VBN from_IN the_DT third_JJ party_NN as_RB well_RB as_IN recording_VBG the_DT interest_NN Under_IN this_DT interpretation_NN ,_, certain_JJ entities_NNS known_VBN as_IN Variable_JJ charge_NN for_IN the_DT period_NN on_IN the_DT outstanding_JJ debt_NN balance_NN ._.
Repayments_NNS Interest_NN Entities_NNPS VIE_NNP must_MD be_VB consolidated_VBN by_IN the_DT primary_JJ made_VBN to_TO third_JJ parties_NNS in_IN the_DT form_NN of_IN royalty_NN payments_NNS that_WDT are_VBP beneficiary_NN of_IN the_DT entity_NN ._.
The_DT primary_JJ beneficiary_NN is_VBZ generally_RB expensed_VBN under_IN UK_NNP GAAP_NNP are_VBP reversed_VBN under_IN US_NNP GAAP_NNP and_CC are_VBP defined_VBN as_IN having_VBG the_DT majority_NN of_IN the_DT risks_NNS and_CC rewards_NNS arising_VBG treated_VBN as_IN repayment_NN of_IN debt_NN ._.
For_IN VIEs_NNS in_IN which_WDT a_DT significant_JJ but_CC not_RB majority_NN variable_JJ interest_NN is_VBZ held_VBN ,_, certain_JJ disclosures_NNS are_VBP required_VBN ._.
The_DT 7_CD Employee_NNP Benefit_NNP Trust_NNP Under_IN UK_NNP GAAP_NNP the_DT Ordinary_NNP Shares_NNP of_IN the_DT Group_NNP is_VBZ in_IN the_DT process_NN of_IN assessing_VBG the_DT impact_NN of_IN this_DT interpretation_NN Company_NN held_VBN by_IN the_DT SkyePharma_NNP PLC_NNP General_NNP Employee_NNP Benefit_NNP as_IN it_PRP will_MD be_VB effective_JJ for_IN the_DT Group_NNP beginning_VBG 1_CD January_NNP 2004_CD ._.
The_DT Trust_NNP are_VBP recorded_VBN at_IN cost_NN and_CC accounted_VBD for_IN as_IN investments_NNS ._.
effect_NN of_IN this_DT interpretation_NN could_MD be_VB that_IN minority_NN investments_NNS The_DT difference_NN between_IN the_DT purchase_NN price_NN of_IN the_DT shares_NNS and_CC the_DT that_IN the_DT Group_NNP holds_VBZ in_IN certain_JJ companies_NNS and_CC which_WDT it_PRP is_VBZ also_RB the_DT exercise_NN price_NN of_IN the_DT award_NN is_VBZ charged_VBN ,_, or_CC credited_VBN ,_, to_TO the_DT profit_NN major_JJ provider_NN of_IN development_NN services_NNS may_MD required_VBN to_TO be_VB and_CC loss_NN account_NN over_IN the_DT period_NN of_IN service_NN in_IN respect_NN of_IN which_WDT the_DT consolidated_JJ if_IN ,_, within_IN the_DT definitions_NNS of_IN the_DT interpretation_NN ,_, the_DT award_NN has_VBZ granted_VBN ._.
Group_NNP maintains_VBZ the_DT majority_NN of_IN the_DT risks_NNS and_CC rewards_NNS of_IN this_DT third-party_JJ entity_NN ._.
Under_IN US_NNP GAAP_NNP the_DT Ordinary_NNP Shares_NNP of_IN the_DT Company_NN purchased_VBN by_IN the_DT Employee_NNP Benefit_NNP Trust_NNP are_VBP accounted_VBN for_IN at_IN cost_NN as_IN treasury_NN In_IN May_NNP 2003_CD ,_, the_DT FASB_NNP issued_VBD FAS_NNP 150_CD ,_, Accounting_NN For_IN Certain_NNP shares_NNS which_WDT reduce_VBP shareholders_NNS funds_NNS ._.
Gains_NNS or_CC losses_NNS arising_VBG Financial_JJ Instruments_NNPS with_IN Characteristics_NNPS of_IN both_DT Liabilities_NNS on_IN subsequent_JJ issuance_NN of_IN the_DT shares_NNS to_TO employees_NNS are_VBP recorded_VBN and_CC Equity_NNP FAS_NNP 150_CD ._.
This_DT standard_JJ establishes_VBZ how_WRB an_DT issuer_NN as_IN adjustments_NNS to_TO shareholders_NNS funds_NNS ._.
The_DT reduction_NN in_IN cost_NN ,_, which_WDT classifies_VBZ and_CC measures_VBZ certain_JJ financial_JJ instruments_NNS with_IN is_VBZ expensed_VBN under_IN UK_NNP GAAP_NNP ,_, is_VBZ reversed_VBN under_IN US_NNP GAAP_NNP to_TO maintain_VB characteristics_NNS of_IN both_DT liabilities_NNS and_CC equity_NN and_CC requires_VBZ that_IN the_DT treasury_NN shares_NNS at_IN cost_NN ._.
All_DT employee_NN compensation_NN expense_NN is_VBZ an_DT issuer_NN classify_VB a_DT financial_JJ instrument_NN that_WDT is_VBZ within_IN its_PRP$ scope_NN recorded_VBN under_IN APB_NNP 25_CD ._.
as_IN a_DT liability_NN or_CC an_DT asset_NN in_IN some_DT circumstances_NNS ._.
FAS_NNP 150_CD will_MD be_VB effective_JJ for_IN financial_JJ instruments_NNS entered_VBD into_IN or_CC modified_VBN after_IN 8_CD Financial_NNP instruments_NNS Under_IN UK_NNP GAAP_NNP ,_, periodic_JJ gains_NNS and_CC losses_NNS 31_CD May_NNP 2003_CD ,_, and_CC otherwise_RB is_VBZ effective_JJ for_IN the_DT group_NN for_IN periods_NNS on_IN interest_NN and_CC foreign_JJ currency_NN derivatives_NNS are_VBP not_RB recognized_VBN beginning_NN after_IN 10_CD June_NNP 2003_CD ._.
The_DT Group_NNP believes_VBZ that_IN the_DT adoption_NN until_IN the_DT operational_JJ transactions_NNS to_TO which_WDT they_PRP are_VBP linked_VBN occur_VBP ._.
of_IN this_DT standard_NN will_MD not_RB have_VB a_DT material_NN effect_NN on_IN the_DT groups_NNS Under_IN US_NNP GAAP_NNP ,_, the_DT Group_NNP records_NNS all_DT derivative_JJ instruments_NNS on_IN results_NNS of_IN operation_NN or_CC financial_JJ position_NN ._.
the_DT balance_NN sheet_NN at_IN fair_JJ value_NN with_IN changes_NNS in_IN fair_JJ values_NNS are_VBP recorded_VBN in_IN earnings_NNS ._.
The_DT Group_NNP has_VBZ also_RB reviewed_VBN its_PRP$ contractual_JJ arrangements_NNS for_IN the_DT existence_NN of_IN embedded_VBN derivatives_NNS that_WDT should_MD be_VB separately_RB accounted_VBN for_IN under_IN SFAS_NNP 133_CD ._.
If_IN embedded_VBN derivatives_NNS are_VBP identified_VBN ,_, they_PRP are_VBP recorded_VBN separately_RB from_IN their_PRP$ host_NN contracts_NNS at_IN fair_JJ value_NN ,_, with_IN changes_NNS in_IN fair_JJ value_NN recognized_VBN in_IN current_JJ earnings_NNS ._.
``_`` Recent_JJ US_NNP GAAP_NNP Pronouncements_NNP In_IN November_NNP 2002_CD ,_, the_DT Emerging_VBG Issues_NNS Task_NNP Force_NNP EITF_NNP reached_VBD a_DT consensus_NN on_IN EITF_NNP 00-21_CD ,_, ''_'' ``_`` Revenue_NN Arrangements_NNS with_IN Multiple_NNP Deliverables_NNP ,_, ''_'' ''_'' related_VBN to_TO the_DT timing_NN of_IN revenue_NN recognition_NN for_IN arrangements_NNS in_IN which_WDT goods_NNS or_CC services_NNS or_CC both_DT are_VBP delivered_VBN separately_RB in_IN a_DT bundled_VBN sales_NNS arrangement_NN ._. ''_''
The_DT EITF_NNP requires_VBZ that_IN when_WRB the_DT deliverables_NNS included_VBD in_IN this_DT type_NN of_IN arrangement_NN meet_VBP certain_JJ criteria_NNS they_PRP should_MD be_VB accounted_VBN for_IN separately_RB as_IN separate_JJ units_NNS of_IN accounting_NN ._.
This_DT may_MD result_VB in_IN a_DT difference_NN in_IN the_DT timing_NN of_IN revenue_NN recognition_NN ,_, but_CC will_MD not_RB result_VB in_IN a_DT change_NN in_IN the_DT total_JJ amount_NN of_IN revenue_NN recognized_VBN in_IN a_DT bundled_VBN sales_NNS arrangement_NN ._.
The_DT allocation_NN of_IN revenue_NN to_TO the_DT separate_JJ deliverables_NNS is_VBZ based_VBN on_IN the_DT relative_JJ fair_JJ value_NN of_IN each_DT item_NN ._.
If_IN the_DT fair_JJ value_NN SkyePharma_NNP annual_JJ report_NN 2003_CD company_NN information_NN and_CC advisors_NNS Registered_NNP and_CC Head_NNP Office_NNP Bankers_NNP 105_CD Piccadilly_NNP ,_, National_NNP Westminster_NNP Bank_NNP plc_NN London_NNP W1J_NNP 7NJ_NNP Bishopsgate_NNP Business_NNP Centre_NNP Telephone_NNP :_: 020 7491 1777_CD PO_NNP Box_NNP 34_CD Fax_NNP :_: 020 7491 3338_CD 15_CD Bishopsgate_NNP Registered_NNP No_NNP :_: 107582_CD London_NNP EC2P_NNP 2AP_NNP Secretary_NNP :_: Douglas_NNP Parkhill_NNP Registrars_NNPS Auditors_NNS Capita_NNP Registrars_NNPS LLP_NNP The_DT Registry_NNP Chartered_NNP Accountants_NNPS 34_CD Beckenham_NNP Road_NNP 1_CD Embankment_NNP Place_NNP Beckenham_NNP London_NNP WC2N_NNP 6RH_NNP Kent_NNP BR3_NNP 4TU_NNP Solicitors_NNPS Depository_NNP UK_NNP The_NNP Bank_NNP of_IN New_NNP York_NNP Stringer_NNP Saul_NNP 101_CD Barclay_NNP Street_NNP 17_CD Hanover_NNP Square_NNP New_NNP York_NNP London_NNP W1S_NNP 1HU_NNP NY_NNP 10286_CD USA_NNP US_NNP Sullivan_NNP &_CC Cromwell_NNP One_CD New_NNP Fetter_NNP Lane_NNP London_NNP EC4A_NNP 1AN_NNP Corporate_NNP Broker_NNP and_CC financial_JJ adviser_NN Credit_NNP Suisse_NNP First_NNP Boston_NNP 20_CD Columbus_NNP Courtyard_NNP London_NNP E14_NNP 4DA_NNP skyepharma_NN ._.
